News Roche inks pipeline deals with Orionis, PeptiDream Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87
News Astellas builds in protein degraders with PeptiDream deal Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.